Article Text

Download PDFPDF
Randomised controlled trial
Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients
  1. Corrado Tamburino,
  2. Piera Capranzano
  1. Cardiovascular Department, Ferrarotto Hospital University of Catania, Catania, Italy
  1. Correspondence to: Professor Corrado Tamburino, Cardiovascular Department, Ferrarotto Hospital University of Catania, Citelli 1, Catania 95124, Italy; professortamburino{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Evidence derived from randomised clinical trials support transcatheter aortic valve replacement (TAVR) as a choice for patients with aortic stenosis with a prohibitive surgical risk and as a valid alternative therapy for those at high-risk of surgical mortality. Owing to increases in operator experience as well as improvements with transcatheter techniques and devices associated with reduction in procedural complications, TAVR has been progressively extended to less risky patients,1 despite the lack of rigorous clinical-trial assessment of this expansion. In the Placement of Aortic Transcatheter Valves 2 (PARTNER-2) Cohort A randomised trial, safety and effectiveness of TAVR with a lower-profile second-generation valve system were compared with conventional surgical aortic valve replacement (SAVR) in patients with intermediate-risk clinical …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.